Marché de la transfection au Moyen-Orient et en Afrique – Tendances et prévisions du secteur jusqu’en 2028

Demande de table des matières Demande de table des matières Parler à un analysteParler à un analyste Acheter maintenantAcheter maintenant Renseignez-vous avant d'acheterRenseignez-vous avant Exemple de rapport gratuitExemple de rapport gratuit

Marché de la transfection au Moyen-Orient et en Afrique – Tendances et prévisions du secteur jusqu’en 2028

  • Healthcare
  • Publish Reports
  • Jan 2021
  • MEA
  • 350 Pages
  • Nombre de tableaux : 302
  • Nombre de figures : 60

>Marché de la transfection au Moyen-Orient et en Afrique, par type (transfection transitoire, transfection stable), méthodes (méthodes non virales, méthodes virales), méthodes de transfection CRISPR (méthodes non virales, méthodes virales), produits (réactifs et kits, instrument, logiciel), organisme (cellules de mammifères, plantes, champignons, virus, bactéries), types de molécules (ADN plasmidique, petit ARN interférent (siRNA), protéines, oligonucléotides d'ADN, complexes ribonucléoprotéiques (RNP), autres), application (application in vitro, application in vivo, bioproduction, autres), stade (recherche, préclinique, phases cliniques, commercial), utilisateur final (biopharma, organisations de recherche sous contrat (CRO), organisation de fabrication sous contrat/organisation de développement et de fabrication sous contrat (CMO/CDMO), universités, hôpitaux, laboratoires cliniques, autres), canal de distribution (appel d'offres direct, vente au détail, autres), pays (Arabie saoudite, Afrique du Sud, Émirats arabes unis, Israël, Égypte, reste du Moyen-Orient et Afrique) Tendances et prévisions du secteur jusqu'en 2028

Marché de la transfection au Moyen-Orient et en AfriqueAnalyse et perspectives du marché : marché de la transfection au Moyen-Orient et en Afrique

Le marché de la transfection au Moyen-Orient et en Afrique devrait connaître une croissance du marché au cours de la période de prévision de 2021 à 2028. Data Bridge Market Research analyse que le marché croît avec un TCAC de 8,0 % au cours de la période de prévision de 2021 à 2028 et devrait atteindre 33,81 millions USD d'ici 2028. La demande croissante de gènes chimériques et l'augmentation des occurrences de maladies chroniques sont les principaux moteurs qui ont propulsé la demande du marché au cours de la période de prévision.

La transfection implique l'introduction d'acide nucléique dans les cellules eucaryotes par des méthodes virales et non virales. La méthode de transfection peut surmonter le défi associé au transfert de la membrane chargée négativement. Un produit chimique tel que le phosphate de calcium et le diéthylaminoéthyl (DEAE)-dextran ou des réactifs à base de lipides cationiques réagit avec la couche externe de l'ADN. Il neutralise la charge négative globale, transmet en outre la quantité positive à la molécule et permet ainsi la délivrance de l'ADN. Des méthodes physiques telles que l'électroporation créent des pores minuscules dans la membrane cellulaire en appliquant une tension électrique, permettant l'entrée de l'ADN directement dans le cytoplasme. Le DEAE-dextran est utilisé pour la transfection transitoire ; cependant, la lipofection peut réaliser une transfection stable et peut donc être utilisée pour l'expression protéique à long terme. La transfection médiée par le phosphate de calcium peut également être utilisée pour une transfection stable. La méthode virale de transfection atteint une efficacité de transfection élevée et est utilisée pour plusieurs phases du développement de produits biopharmaceutiques.

L'augmentation de la prévalence des maladies chroniques constitue un moteur de croissance pour le marché de la transfection. Le coût élevé des instruments constitue un frein à la croissance du marché de la transfection. L'exploration des marchés émergents constitue une opportunité pour la croissance du marché de la transfection. La longue procédure d'approbation constitue un défi pour la croissance du marché de la transfection.

Le rapport sur le marché de la transfection fournit des détails sur la part de marché, les nouveaux développements et l'analyse du pipeline de produits, l'impact des acteurs du marché national et localisé, analyse les opportunités en termes de poches de revenus émergentes, de changements dans la réglementation du marché , d'approbations de produits, de décisions stratégiques, de lancements de produits, d'expansions géographiques et d'innovations technologiques sur le marché. Pour comprendre l'analyse et le scénario du marché, contactez-nous pour un briefing d'analyste, notre équipe vous aidera à créer une solution d'impact sur les revenus pour atteindre votre objectif souhaité.

Marché de la transfection au Moyen-Orient et en AfriquePortée et taille du marché de la transfection au Moyen-Orient et en Afrique

Le marché de la transfection est segmenté en fonction du type, des méthodes, des méthodes de transfection CRISPR, des produits, de l'organisme, des types de molécules, de l'application, du stade, de l'utilisateur final et du canal de distribution. La croissance entre les segments vous aide à analyser les niches de croissance et les stratégies pour aborder le marché et déterminer vos principaux domaines d'application et la différence entre vos marchés cibles.

  • Sur la base du type, le marché de la transfection est segmenté en transfection transitoire et transfection stable. En 2021, le segment de la transfection transitoire domine car cette méthode obtient des résultats de transfection en 3 à 7 jours avec des taux d'efficacité de transfection élevés.
  • Sur la base des méthodes, le marché de la transfection est segmenté en méthodes non virales et méthodes virales . En 2021, le segment des méthodes non virales domine tous les types de transfection, y compris la transfection CRISPR (courtes répétitions palindromiques groupées et régulièrement espacées), car ces méthodes offrent une efficacité de transfection élevée et surmontent les risques d'infections induites par les méthodes de transfection virale.
  • Sur la base des méthodes de transfection CRISPR, le marché de la transfection est segmenté en méthodes non virales et méthodes virales. En 2021, le segment des méthodes non virales domine la transfection CRISPR (répétitions palindromiques courtes groupées et régulièrement espacées) car il permet une livraison efficace des séquences CRISPR aux lignées cellulaires ciblées.
  • Sur la base des produits, le marché de la transfection est segmenté en réactifs et kits, instruments et logiciels. En 2021, le segment des réactifs et kits domine car ils sont utilisés pour améliorer l'efficacité du processus de transfection dans diverses expériences génétiques.
  • Sur la base de l'organisme, le marché de la transfection est segmenté en cellules de mammifères, plantes, champignons, virus et bactéries . En 2021, le segment des cellules de mammifères domine car les cellules de mammifères sont largement utilisées pour la production d'anticorps monoclonaux, de protéines, d'urokinase, d'hormones folliculo-stimulantes et d'autres produits par rapport aux autres types de lignées cellulaires.
  • On the basis of types of molecule, the transfection market is segmented into plasmid DNA, small interfering RNA (siRNA), proteins, DNA oligonucleotides, ribonucleoprotein complexes (RNPs) and others. In 2021, plasmid DNA segment is dominating as large number of transfection technologies have initially been developed for transfer of plasmid DNA into cells.
  • On the basis of application, the transfection market is segmented into in vitro application, in vivo application, bioproduction and others. In 2021, in vitro application segment is dominating as it provides with the delivery of cargo nucleic acid molecules into cultured cells which has a crucial role in research as well as for commercial production of molecules.
  • On the basis of stage, the transfection market is segmented into research, preclinical, clinical phases and commercial. In 2021, research segment is dominating due to increasing demand for gene expression across synthetic biology industry and other applications.
  • On the basis of end user, the transfection market is segmented into biopharma, contract research organizations (CROs), contract manufacturing organization/contract development and manufacturing organization (CMOs/CDMOs), academia, hospitals, clinical labs and others. In 2021, biopharma segment hold the largest market share because of the increasing demand to improve efficiency & speed for production of desired cell lines.
  • On the basis of distribution channel, the transfection market is segmented into direct tender, retail sales and others. In 2021, direct tender segment is dominating as it is the primary source of procurement across different end users.

Middle East and Africa Transfection Market Country Level Analysis

The transfection market is analyzed and market size information is provided on the basis of country, type, methods, CRISPR transfection methods, products, organism, types of molecule, application, stage, end user and distribution channel as referenced above.

The countries covered in the Middle East and Africa transfection market report are report are the Saudi Arabia, South Africa, UAE, Israel, Egypt, Rest of Middle East & Africa.

Middle East and Africa is expected to grow with the substantial growth rate in the forecast period of 2021 to 2028 as Middle East and Africa counties are focused on utilization of biopharmaceuticals in the production of proteins and also using best therapeutic options for treatment of increasing chronic diseases. South Africa is dominating in Middle East and Africa due to increasing focus on stable cell line generation and virus production.

The country section of the transfection market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East & Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Surging Levels of Investment and Growing Demand of Chimeric Genes are boosting the Market Growth of Transfection

Transfection market also provides you with detailed market analysis for every country growth in transfection industry with transfection drugs sales, impact of advancement in the transfection technology and changes in regulatory scenarios with their support for the transfection market. The data is available for historic period 2010 to 2018.

Competitive Landscape and Transfection Market Share Analysis

Middle East and Africa transfection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to Middle East and Africa transfection market.

The major companies which are dealing in the Middle East and Africa transfection market are Mirus Bio LLC., Promega Corporation, Bio-Rad Laboratories, Inc., Merck KGaA, Lonza, MaxCyte, Inc., Cytiva, Thermofisher Scientific Inc., QIAGEN, OriGene Technologies, Inc. and SignaGen Laboratories among others. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the transfection market.

For instance,

  • In November 2020, Thermofisher Scientific Inc. collaborated with Northeastern University to strengthen the biopharmaceutical industry's innovation and capabilities and gene and cell therapies. The company is continuously engaged in manufacturing innovative and advanced reagents and techniques to deliver sensitivity and accuracy to the ongoing experiments and drug development. This collaboration thus allowed the company to drive the growth of valuable and highly efficient reagents and tools utilized in the transfection procedure.
  • En juillet 2019, Mirus Bio LLC. a lancé un nouveau produit testé de qualité, le réactif de transfection TransIT-VirusGEN SELECT, indiqué pour une distribution efficace de l'ADN afin de produire des vecteurs viraux à grande échelle et à titre élevé. Ce réactif a la capacité d'améliorer la distribution de l'ADN vecteur d'emballage et de transfert aux types de cellules HEK 293 adhérentes et aux suspensions d'ADN. Le lancement de ce produit a enrichi le portefeuille de produits de la société et a stimulé ses revenus.

La collaboration, le lancement de produits, l'expansion commerciale, les récompenses et la reconnaissance, les coentreprises et d'autres stratégies des acteurs du marché améliorent le marché de l'entreprise sur le marché de la transfection, ce qui offre également l'avantage à l'organisation d'améliorer son offre de transfection.


SKU-

Accédez en ligne au rapport sur le premier cloud mondial de veille économique

  • Tableau de bord d'analyse de données interactif
  • Tableau de bord d'analyse d'entreprise pour les opportunités à fort potentiel de croissance
  • Accès d'analyste de recherche pour la personnalisation et les requêtes
  • Analyse de la concurrence avec tableau de bord interactif
  • Dernières actualités, mises à jour et analyse des tendances
  • Exploitez la puissance de l'analyse comparative pour un suivi complet de la concurrence
Demande de démonstration

Table des matières

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TRANSIENT TRANSFECTION OF TRANSFECTION LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 TOTAL ADDRESSABLE MARKET

4.1.1 BY METHOD/MODALITY

4.1.2 BY END USER

4.1.3 BY APPLICATION

4.1.4 BY STAGE

4.2 EARLY AND LATE STAGE CELL LINE DEVELOPMENT FOR BIOPHARMA AND VIRAL VECTOR PRODUCTION FOR GENE THERAPY

4.2.1 THE LIST OF APPROVED ANTIBODIES PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS AND LIST OF SELECTABLE MARKERS USED IN MAMMALIAN EXPRESSION VECTORS

5 REGULATORY FRAMEWORK

5.1 EUROPEAN UNION REGULATORY SCENARIO

5.2 U.S. REGULATORY SCENARIO

5.3 JAPAN REGULATORY SCENARIO

5.4 CHINA REGULATORY SCENARIO

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISE IN THE PREVALENCE OF CHRONIC DISEASES

6.1.2 DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS

6.1.3 GROWING DEMAND OF CHIMERIC GENES

6.1.4 LARGE-SCALE TRANSFECTIONS USED IN CLINICAL RESEARCH

6.1.5 UTILIZATION OF BIOPHARMACEUTICALS IN THE PRODUCTION OF PROTEINS

6.2 RESTRAINTS

6.2.1 HIGH COST OF TRANSFECTION PRODUCTS

6.2.2 SELECTIVE EFFECTIVENESS OF TRANSFECTION REAGENTS

6.2.3 CELL DAMAGE INDUCED BY TRANSFECTION PROCEDURE

6.3 OPPORTUNITIES

6.3.1 EXPLORATION OF EMERGING MARKET

6.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.3 INCREASING GOVERNMENT SUPPORT

6.3.4 SURGING LEVEL OF INVESTMENT

6.4 CHALLENGES

6.4.1 LONG APPROVAL PROCEDURE

6.4.2 LACK OF SAFETY LEVEL LAB FOR VIRUS ASSOCIATED TRANSFECTION

6.4.3 LACK OF TRAINED PROFESSIONALS

7 COVID-19 IMPACT OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN HEALTHCARE INDUSTRY

7.1 OVERVIEW

7.2 IMPACT ON THE PRICE

7.3 IMPACT ON DEMAND

7.4 IMPACT ON SUPPLY CHAIN

7.5 STRATEGIC INITIATIVE BY MANUFACTURERS

7.6 CONCLUSION

8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE

8.1 OVERVIEW

8.2 TRANSIENT TRANSFECTION

8.2.1 BY STAGE

8.2.1.1 RESEARCH

8.2.1.2 PRECLINICAL

8.2.1.3 CLINICAL PHASES

8.2.1.4 COMMERCIAL

8.2.2 BY PRODUCT

8.2.2.1 REAGENT & KITS

8.2.2.2 INSTRUMENTS

8.2.2.3 SOFTWARE

8.3 STABLE TRANSECTION

8.3.1 BY STAGE

8.3.1.1 RESEARCH

8.3.1.2 PRECLINICAL

8.3.1.3 CLINICAL PHASES

8.3.1.4 COMMERCIAL

8.3.2 BY PRODUCT

8.3.2.1 REAGENT & KITS

8.3.2.2 INSTRUMENTS

8.3.2.3 SOFTWARE

9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS

9.1 2.1 OVERVIEW

9.2 NON- VIRAL METHODS

9.2.1 CHEMICAL

9.2.1.1 Lipofection Method

9.2.1.2 Calcium Phosphate Precipitation Method

9.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method

9.2.1.4 Others

9.2.2 PHYSICAL

9.2.2.1 Electroporation

9.2.2.2 Direct Microinjection

9.2.2.3 Biolistic Particle Delivery/ Particle Bombardment

9.2.2.4 Magnetofection

9.2.2.5 Sonoporation

9.2.2.6 Others

9.3 VIRAL METHODS

9.3.1 RETROVIRUS TRANSFECTION

9.3.2 ADENOVIRUS TRANSFECTION

9.3.3 LENTIVIRUS TRANSFECTION

9.3.4 OTHERS

10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS

10.1 OVERVIEW

10.2 NON- VIRAL METHODS

10.2.1 CHEMICAL

10.2.1.1 Lipofection Method

10.2.1.2 Calcium Phosphate Precipitation Method

10.2.1.3 Polyethylenimine (PEI)–DNA Condensation Method

10.2.1.4 Others

10.2.2 PHYSICAL

10.2.2.1 Electroporation

10.2.2.2 Direct Microinjection

10.2.2.3 Biolistic Particle Delivery/ Particle Bombardment

10.2.2.4 Magnetofection

10.2.2.5 Sonoporation

10.2.2.6 Others

10.3 VIRAL METHODS

10.3.1 RETROVIRUS TRANSFECTION

10.3.2 ADENOVIRUS TRANSFECTION

10.3.3 LENTIVIRUS TRANSFECTION

10.3.4 OTHERS

11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY PRODUCTS

11.1 OVERVIEW

11.2 REAGENTS & KITS

11.2.1 CATIONIC LIPIDS

11.2.1.1 Liposomal Reagents

11.2.1.1.1 L-Dioleoyl Phosphatidylethanolamine (DOPE)

11.2.1.1.2 DOTAP [1,2-Dioleoyloxy-3-Trimethylammonium Propane]

11.2.1.1.3 DOTMA [N-[1(2,3-Dioleoyloxy)Propyl]-N,N,N-Trimethylammonium Chloride]

11.2.1.1.4 Others

11.2.1.2 Non-Liposomal Reagents

11.2.1.2.1 DNA Transfection Reagent

11.2.1.2.2 siRNA Transfection Reagent

11.2.1.2.3 Others

11.2.2 CATIONIC POLYMER

11.2.2.1 DEAE-Dextran

11.2.2.2 Polybrene

11.2.2.3 Polyethyleneimine

11.2.2.4 Dendrimers

11.2.2.5 Others

11.2.3 NANOPARTICLES

11.2.3.1 Systemic Intravenous Injection

11.2.3.2 Direct Intratumoral Injection

11.2.4 KITS

11.2.4.1 Transporter Transfection Reagent

11.2.4.2 GMP Transfection Reagent

11.2.4.3 Neon Electroporation

11.2.4.4 Cellfectin Ii Transfection Reagent

11.2.4.5 DMRIE-C Transfection Reagent

11.2.4.6 Lipofectamine Transfection Reagent

11.2.4.7 Lipofectin Transfection Reagent

11.2.4.8 Oligofectamine Transfection Reagent

11.2.4.9 Optifect Transfection Reagent

11.2.4.10 Cell Specific Transfection Reagent

11.2.4.11 Gene Gun Kit

11.2.4.12 Plasmid Transfection Reagent

11.2.4.13 Others

11.2.5 CUVETTE CHAMBER

11.2.6 OTHERS

11.3 INSTRUMENT

11.3.1 ELECTROPORATION SYSTEM

11.3.1.1 Neon Transfection System

11.3.1.2 Others

11.3.2 ELECTRO-CELL FUSION GENERATOR

11.3.3 ELECTRO-KINETIC TRANSFECTION SYSTEM

11.3.4 HEPTA SYSTEM

11.3.5 TUBING PREP STATION

11.3.6 RT-PCR

11.3.7 GUN SYSTEM

11.3.8 MICROPLATE READER

11.3.9 SONOPORATION SYSTEM

11.3.10 MICROSCOPES

11.3.11 OTHERS

12 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY ORGANISM

12.1 OVERVIEW

12.2 MAMMALIAN CELLS

12.3 PLANTS

12.4 FUNGI

12.5 VIRUS

12.6 BACTERIA

13 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE

13.1 OVERVIEW

13.2 PLASMID DNA

13.3 SMALL INTERFERING RNA (SIRNA)

13.4 PROTEINS

13.5 DNA OLIGONUCLEOTIDES

13.6 RIBONUCLEOPROTEIN COMPLEXES (RNPS)

13.7 OTHERS

14 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY APPLICATION

14.1 OVERVIEW

14.2 BY TYPE

14.2.1 IN VITRO APPLICATION

14.2.1.1 Gene Expression

14.2.1.2 RNA Interference

14.2.2 IN VIVO APPLICATION

14.2.2.1 Gene Therapy

14.2.2.2 Cellular-Based Therapy

14.2.3 BIOPRODUCTION

14.2.3.1 Antibody/Protein Production

14.2.3.2 Virus Production

14.2.4 OTHERS

14.3 BY INDUSTRY

14.3.1 SYNTHETIC BIOLOGY

14.3.1.1 Biopharma

14.3.1.2 Monoclonal Antibodies (mAbs)

14.3.1.3 Recombinant Proteins

14.3.1.4 Biofuels

14.3.1.5 Cell Line Development

14.3.1.6 Flavors & Fragrances

14.3.1.7 Enzyme Engineering & Production

14.3.1.8 Specialty Chemicals

14.3.2 AGRICULTURE

14.3.3 OTHERS

15 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY STAGES

15.1 OVERVIEW

15.2 RESEARCH

15.3 PRECLINICAL

15.4 CLINICAL PHASES

15.5 COMMERCIAL

16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY END USER

16.1 OVERVIEW

16.2 BIOPHARMA

16.3 CONTRACT RESEARCH ORGANIZATIONS (CROS)

16.4 CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS)

16.5 ACADEMIA

16.6 HOSPITALS

16.7 CLINICAL LABS

16.8 OTHERS

17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 DIRECT TENDERS

17.3 RETAIL SALES

17.4 OTHERS

18 MIDDLE EAST AND AFRICA TRASNFECTION MARKET, BY GEOGRAPHY

18.1 MIDDLE EAST & AFRICA

18.1.1 SOUTH AFRICA

18.1.2 SAUDI ARABIA

18.1.3 UAE

18.1.4 ISRAEL

18.1.5 EGYPT

18.1.6 REST OF MIDDLE EAST & AFRICA

19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

20 SWOT ANALYSIS

21 COMPANY PROFILE

21.1 THERMOFISHER SCIENTIFIC INC.

21.1.1 COMPANY SNAPSHOT

21.1.2 REVENUE ANALYSIS

21.1.3 COMPANY SHARE ANALYSIS

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENTS

21.2 ROCHE MOLECULAR SYSTEMS, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)

21.2.1 COMPANY SNAPSHOT

21.2.2 REVENUE ANALYSIS

21.2.3 COMAPYN SHARE ANALYSIS

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 QIAGEN

21.3.1 COMPANY SNAPSHOT

21.3.2 REVENUE ANALYSIS

21.3.3 COMPANY SHARE ANALYSIS

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 PROMEGA CORPORATION

21.4.1 COMPANY SNAPSHOT

21.4.2 COMPANY SHARE ANALYSIS

21.4.3 PRODUCT PORTFOLIO

21.4.4 RECENT DEVELOPMENTS

21.5 TAKARA BIO INC.

21.5.1 COMPANY SNAPSHOT

21.5.2 REVENUE ANALYSIS

21.5.3 COMPANY SHARE ANALYSIS

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENTS

21.6 BIO-RAD LABORATORIES, INC.

21.6.1 COMPANY SNAPSHOT

21.6.2 REVENUE ANANLYSIS

21.6.3 PRODUCT PORTFOLIO

21.6.4 RECENT DEVELOPMENT

21.7 LONZA

21.7.1 COMPANY SNAPSHOT

21.7.2 REVENUE ANANLYSIS

21.7.3 PRODUCT PORTFOLIO

21.7.4 RECENT DEVELOPMENTS

21.8 CYTIVA

21.8.1 COMPANY SNAPSHOT

21.8.2 PRODUCT PORTFOLIO

21.8.3 RECENT DEVELOPMENTS

21.9 ALTOGEN BIOSYSTEMS

21.9.1 COMPANY SNAPSHOT

21.9.2 PRODUCT PORTFOLIO

21.9.3 RECENT DEVELOPMENTS

21.1 AMYRIS

21.10.1 COMPANY SNAPSHOT

21.10.2 REVENUE ANALYSIS

21.10.3 PRODUCT PORTFOLIO

21.10.4 RECENT DEVELOPMENTS

21.11 APPLIED BIOLOGICAL MATERIALS INC. (ABM)

21.11.1 COMPANY SNAPSHOT

21.11.2 PRODUCT PORTFOLIO

21.11.3 RECENT DEVELOPMENT

21.12 AUTOLUS

21.12.1 COMPANY SNAPSHOT

21.12.2 PRODUCT PORTFOLIO

21.12.3 RECENT DEVELOPMENTS

21.13 AVANTI POLAR LIPIDS (A SUBSIDIARY OF CRODA INTERNATIONAL PLC)

21.13.1 COMPANY SNAPSHOT

21.13.2 REVENUE ANALYSIS

21.13.3 PRODUCT PORTFOLIO

21.13.4 RECENT DEVELOPMENT

21.14 BECKMAN COULTER, INC. (A SUBSIDIARY OF DANAHER)

21.14.1 COMPANY SNAPSHOT

21.14.2 REVENUE ANALYSIS

21.14.3 PRODUCT PORTFOLIO

21.14.4 RECENT DEVELOPMENTS

21.15 CODEXIS

21.15.1 COMPANY SNAPSHOT

21.15.2 REVENUE ANALYSIS

21.15.3 PRODUCT PORTFOLIO

21.15.4 RECENT DEVELOPMENTS

21.16 CONAGEN, INC.

21.16.1 COMPANY SNAPSHOT

21.16.2 PRODUCT PORTFOLIO

21.16.3 RECENT DEVELOPMENTS

21.17 FUJIFILM IRVINE SCIENTIFIC (A SUBSIDIARY OF FUJIFILM HOLDINGS CORPORATION)

21.17.1 COMPANY SNAPSHOT

21.17.2 REVENUE ANANLYSIS

21.17.3 PRODUCT PORTFOLIO

21.17.4 RECENT DEVELOPMENT

21.18 GENLANTIS INC.

21.18.1 COMPANY SNAPSHOT

21.18.2 PRODUCT PORTFOLIO

21.18.3 RECENT DEVELOPMENTS

21.19 GENO TECHNOLOGY INC., USA

21.19.1 COMPANY SNAPSHOT

21.19.2 PRODUCT PORTFOLIO

21.19.3 RECENT DEVELOPMENTS

21.2 GINKGO BIOWORKS

21.20.1 COMPANY SNAPSHOT

21.20.2 PRODUCT PORTFOLIO

21.20.3 RECENT DEVELOPMENTS

21.21 IMPOSSIBLE FOODS INC.

21.21.1 COMPANY SNAPSHOT

21.21.2 PRODUCT PORTFOLIO

21.21.3 RECENT DEVELOPMENTS

21.22 MAXCYTE, INC.

21.22.1 COMPANY SNAPSHOT

21.22.2 REVENUE ANALYSIS

21.22.3 PRODUCT PORTFOLIO

21.22.4 RECENT DEVELOPMENTS

21.23 MERCK KGAA

21.23.1 COMPANY SNAPSHOT

21.23.2 REVENUE ANALYSIS

21.23.3 PRODUCT PORTFOLIO

21.23.4 RECENT DEVELOPMENTS

21.24 MIRUS BIO LLC.

21.24.1 COMPANY SNAPSHOT

21.24.2 PRODUCT PORTFOLIO

21.24.3 RECENT DEVELOPMENTS

21.25 ORIGENE TECHNOLOGIES, INC.

21.25.1 COMPANY SNAPSHOT

21.25.2 PRODUCT PORTFOLIO

21.25.3 RECENT DEVELOPMENTS

21.26 PERKINELMER CHEMAGEN TECHNOLOGIE GMBH (A SUBSIDIARY OF PERKINELMER INC.)

21.26.1 COMPANY SNAPSHOT

21.26.2 REVENUE ANANLYSIS

21.26.3 PRODUCT PORTFOLIO

21.26.4 RECENT DEVELOPMENTS

21.27 POLYPLUS TRANSFECTION

21.27.1 COMPANY SNAPSHOT

21.27.2 PRODUCT PORTFOLIO

21.27.3 RECENT DEVELOPMENTS

21.28 POSEIDA THERAPEUTICS, INC.

21.28.1 COMPANY SNAPSHOT

21.28.2 PRODUCT PORTFOLIO

21.28.3 RECENT DEVELOPMENTS

21.29 R&D SYSTEMS, INC.

21.29.1 COMPANY SNAPSHOT

21.29.2 PRODUCT PORTFOLIO

21.29.3 RECENT DEVELOPMENT

21.3 SBS GENETECH

21.30.1 COMPANY SNAPSHOT

21.30.2 PRODUCT PORTFOLIO

21.30.3 RECENT DEVELOPMENTS

21.31 SIGNAGEN LABORATORIES

21.31.1 COMPANY SNAPSHOT

21.31.2 PRODUCT PORTFOLIO

21.31.3 RECENT DEVELOPMENTS

21.32 TWIST BIOSCIENCE

21.32.1 COMPANY SNAPSHOT

21.32.2 REVENUE ANALYSIS

21.32.3 PRODUCT PORTFOLIO

21.32.4 RECENT DEVELOPMENTS

21.33 VERVE THERAPEUTICS, INC.

21.33.1 COMPANY SNAPSHOT

21.33.2 PRODUCT PORTFOLIO

21.33.3 RECENT DEVELOPMENTS

21.34 ZYMERGEN INC.

21.34.1 COMPANY SNAPSHOT

21.34.2 PRODUCT PORTFOLIO

21.34.3 RECENT DEVELOPMENTS

22 QUESTIONNAIRE

23 RELATED REPORTS

Liste des tableaux

LIST OF TABLES

TABLE 1 LIST OF APPROVED ANTIBODIES PRODUCED IN CHO CELLS

TABLE 2 EU DIRECTIVES AND REGULATIONS RELATED TO CLINICAL TRIALS INVOLVING GTMPS

TABLE 3 GOVERNMENT ENTITIES THAT ARE IN CHARGE OF TYPE 2 USES

TABLE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA NON- VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA SOFTWARE BY INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 36 NORTH AMERICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA MAMMALIAN CELLS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA PLANTS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA FUNGI IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA VIRUS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA PLASMID DNA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA PROTEINS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA DNA OLIGONUCLEOTIDES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA RIBONUCLEOPROTEIN COMPLEXES (RNPS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA BACTERIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 51 NORTH AMERICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 53 NORTH AMERICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA BIOPRODUCTION IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 55 NORTH AMERICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 59 NORTH AMERICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA AGRICULTURE IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 62 NORTH AMERICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA RESEARCH IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA PRE-CLINICAL IN TRANSFECTION MARKET, BY REGION, 2017-2027 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA CLINICAL PHASES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA COMMERCIAL IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 67 NORTH AMERICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA BIOPHARMA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA CONTRACT RESEARCH ORGANIZATIONS (CROS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA CONTRACT MANUFACTURING ORGANIZATION/ CONTRACT DEVELOPMENT AND MANUFACTURING ORGANIZATION (CMOS/CDMOS) IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA ACADEMIA IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA HOSPITALS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA CLINICAL LABS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 74 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 75 NORTH AMERICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 76 MIDDLE EAST AND AFRICA DIRECT TENDER IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 77 MIDDLE EAST AND AFRICA RETAIL SALES IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 78 MIDDLE EAST AND AFRICA OTHERS IN TRANSFECTION MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 79 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY REGION, 2018-2028 (USD MILLION)

TABLE 80 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 81 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 82 MIDDLE EAST & AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 83 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 84 MIDDLE EAST & AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 85 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 86 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 87 MIDDLE EAST & AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 88 MIDDLE EAST & AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 89 MIDDLE EAST & AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 90 MIDDLE EAST & AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 91 MIDDLE EAST & AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 92 MIDDLE EAST & AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 93 MIDDLE EAST & AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 94 MIDDLE EAST & AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 95 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 96 MIDDLE EAST & AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 97 MIDDLE EAST & AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 98 MIDDLE EAST & AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 99 MIDDLE EAST & AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 100 MIDDLE EAST & AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 101 MIDDLE EAST & AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 102 MIDDLE EAST & AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 103 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 104 MIDDLE EAST & AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 105 MIDDLE EAST & AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 106 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 107 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 108 MIDDLE EAST & AFRICATRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 109 MIDDLE EAST & AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 110 MIDDLE EAST & AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 111 MIDDLE EAST & AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 112 MIDDLE EAST & AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 113 MIDDLE EAST & AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 114 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 115 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 116 MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 117 SOUTH AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 118 SOUTH AFRICA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 119 SOUTH AFRICA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 120 SOUTH AFRICA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 121 SOUTH AFRICA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 122 SOUTH AFRICA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 123 SOUTH AFRICA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 124 SOUTH AFRICA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 125 SOUTH AFRICA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 126 SOUTH AFRICA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 127 SOUTH AFRICA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 128 SOUTH AFRICA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 129 SOUTH AFRICA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 130 SOUTH AFRICA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 131 SOUTH AFRICA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 132 SOUTH AFRICA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 133 SOUTH AFRICA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 134 SOUTH AFRICA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 135 SOUTH AFRICA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 136 SOUTH AFRICA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 137 SOUTH AFRICA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 138 SOUTH AFRICA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 139 SOUTH AFRICA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 140 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 141 SOUTH AFRICA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 142 SOUTH AFRICA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 143 SOUTH AFRICA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 144 SOUTH AFRICA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 145 SOUTH AFRICA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 146 SOUTH AFRICA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 147 SOUTH AFRICA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 148 SOUTH AFRICA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 149 SOUTH AFRICA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 150 SOUTH AFRICA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 151 SOUTH AFRICA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 152 SOUTH AFRICA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 153 SOUTH AFRICA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 154 SAUDI ARABIA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 155 SAUDI ARABIA TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 156 SAUDI ARABIA TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 157 SAUDI ARABIA STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 158 SAUDI ARABIA STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 159 SAUDI ARABIA TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 160 SAUDI ARABIA NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 161 SAUDI ARABIA CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 162 SAUDI ARABIA PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 163 SAUDI ARABIA VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 164 SAUDI ARABIA CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 165 SAUDI ARABIA NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 166 SAUDI ARABIA CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 167 SAUDI ARABIA PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 168 SAUDI ARABIA VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 169 SAUDI ARABIA TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 170 SAUDI ARABIA REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 171 SAUDI ARABIA CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 172 SAUDI ARABIA LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 173 SAUDI ARABIA NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 174 SAUDI ARABIA CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 175 SAUDI ARABIA KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 176 SAUDI ARABIA NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 177 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 178 SAUDI ARABIA INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 179 SAUDI ARABIA ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 180 SAUDI ARABIA TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 181 SAUDI ARABIA TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 182 SAUDI ARABIA TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 183 SAUDI ARABIA IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 184 SAUDI ARABIA IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 185 SAUDI ARABIA BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 186 SAUDI ARABIA TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 187 SAUDI ARABIA SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 188 SAUDI ARABIA TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 189 SAUDI ARABIA TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 190 SAUDI ARABIA TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 191 UAE TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 192 UAE TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 193 UAE TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 194 UAE STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 195 UAE STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 196 UAE TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 197 UAE NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 198 UAE CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 199 UAE PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 200 UAE VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 201 UAE CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 202 UAE NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 203 UAE CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 204 UAE PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 205 UAE VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 206 UAE TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 207 UAE REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 208 UAE CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 209 UAE LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 210 UAE NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 211 UAE CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 212 UAE KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 213 UAE NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 214 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 215 UAE INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 216 UAE ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 217 UAE TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 218 UAE TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 219 UAE TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 220 UAE IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 221 UAE IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 222 UAE BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 223 UAE TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 224 UAE SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 225 UAE TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 226 UAE TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 227 UAE TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 228 ISRAEL TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 229 ISRAEL TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 230 ISRAEL TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 231 ISRAEL STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 232 ISRAEL STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 233 ISRAEL TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 234 ISRAEL NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 235 ISRAEL CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 236 ISRAEL PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 237 ISRAEL VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 238 ISRAEL CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 239 ISRAEL NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 240 ISRAEL CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 241 ISRAEL PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 242 ISRAEL VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 243 ISRAEL TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 244 ISRAEL REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 245 ISRAEL CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 246 ISRAEL LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 247 ISRAEL NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 248 ISRAEL CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 249 ISRAEL KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 250 ISRAEL NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 251 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 252 ISRAEL INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 253 ISRAEL ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 254 ISRAEL TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 255 ISRAEL TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 256 ISRAEL TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 257 ISRAEL IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 258 ISRAEL IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 259 ISRAEL BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 260 ISRAEL TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 261 ISRAEL SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 262 ISRAEL TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 263 ISRAEL TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 264 ISRAEL TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 265 EGYPT TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

TABLE 266 EGYPT TRANSIENT TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 267 EGYPT TRANSIENT TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 268 EGYPT STABLE TRANSFECTION (BY STAGE) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 269 EGYPT STABLE TRANSFECTION (BY PRODUCT) IN TRANSFECTION MARKET, BY TYPE, 2019-2028 (USD MILLION)

TABLE 270 EGYPT TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 271 EGYPT NON-VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 272 EGYPT CHEMICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 273 EGYPT PHYSICAL IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 274 EGYPT VIRAL METHODS IN TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 275 EGYPT CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 276 EGYPT NON-VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 277 EGYPT CHEMICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 278 EGYPT PHYSICAL IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 279 EGYPT VIRAL METHODS IN CRISPR TRANSFECTION MARKET, BY METHODS, 2019-2028 (USD MILLION)

TABLE 280 EGYPT TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 281 EGYPT REAGENTS & KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 282 EGYPT CATIONIC LIPIDS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 283 EGYPT LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 284 EGYPT NON-LIPOSOMAL REAGENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 285 EGYPT CATIONIC POLYMER IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 286 EGYPT KITS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 287 EGYPT NANOPARTICLES IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 288 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 289 EGYPT INSTRUMENTS IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (UNITS)

TABLE 290 EGYPT ELECTROPORATION SYSTEM IN TRANSFECTION MARKET, BY PRODUCTS, 2019-2028 (USD MILLION)

TABLE 291 EGYPT TRANSFECTION MARKET, BY ORGANISM, 2019-2028 (USD MILLION)

TABLE 292 EGYPT TRANSFECTION MARKET, BY TYPES OF MOLECULE, 2019-2028 (USD MILLION)

TABLE 293 EGYPT TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 294 EGYPT IN VITRO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 295 EGYPT IN VIVO APPLICATION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 296 EGYPT BIOPRODUCTION IN TRANSFECTION MARKET (BY TYPE), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 297 EGYPT TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 298 EGYPT SYNTHETIC BIOLOGY IN TRANSFECTION MARKET (BY INDUSTRY), BY APPLICATION, 2019-2028 (USD MILLION)

TABLE 299 EGYPT TRANSFECTION MARKET, BY STAGE, 2019-2028 (USD MILLION)

TABLE 300 EGYPT TRANSFECTION MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 301 EGYPT TRANSFECTION MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 302 REST OF MIDDLE EAST & AFRICA TRANSFECTION MARKET, BY TYPE, 2018-2028 (USD MILLION)

 

Liste des figures

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA TRANSFECTION MARKET : DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MULTIVARIATE MODELLING

FIGURE 7 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 10 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: SEGMENTATION

FIGURE 12 INCREASING OCCURENCE OF CHRONIC DISEASES AND DEVELOPMENT OF SYNTHETIC BIOLOGY PRODUCTS IS DRIVING THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 TRANSIENT TRANSFECTION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA TRANSFECTION MARKET IN 2021 & 2028

FIGURE 14 APPROVAL PROCESS FOR GENE THERAPY IN CHINA

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA TRANSFECTION MARKET

FIGURE 16 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020

FIGURE 17 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, 2020-2028 (USD MILLION)

FIGURE 18 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 19 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020

FIGURE 21 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)

FIGURE 22 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)

FIGURE 23 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE

FIGURE 24 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020

FIGURE 25 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, 2020-2028 (USD MILLION)

FIGURE 26 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, CAGR (2021-2028)

FIGURE 27 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY METHODS, LIFELINE CURVE

FIGURE 28 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020

FIGURE 29 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, 2020-2028 (USD MILLION)

FIGURE 30 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 31 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 32 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020

FIGURE 33 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, 2020-2028 (USD MILLION)

FIGURE 34 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, CAGR (2021-2028)

FIGURE 35 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY ORGANISM, LIFELINE CURVE

FIGURE 36 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020

FIGURE 37 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, 2020-2028 (USD MILLION)

FIGURE 38 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE, CAGR (2021-2028)

FIGURE 39 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY TYPES OF MOLECULE LIFELINE CURVE

FIGURE 40 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020

FIGURE 41 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, 2020-2028 (USD MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 43 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 44 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020

FIGURE 45 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, 2020-2028 (USD MILLION)

FIGURE 46 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, CAGR (2021-2028)

FIGURE 47 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY STAGES, LIFELINE CURVE

FIGURE 48 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020

FIGURE 49 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, 2020-2028 (USD MILLION)

FIGURE 50 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 51 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY END USER, LIFELINE CURVE

FIGURE 52 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 53 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)

FIGURE 54 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 55 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 56 MIDDLE EAST & AFRICA TRANSFECTION MARKET: SNAPSHOT (2020)

FIGURE 57 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020)

FIGURE 58 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 59 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 60 MIDDLE EAST & AFRICA TRANSFECTION MARKET: BY TYPE (2021-2028)

FIGURE 1 MIDDLE EAST AND AFRICA TRANSFECTION MARKET: COMPANY SHARE 2020 (%)

 

Voir les informations détaillées Right Arrow

Méthodologie de recherche

La collecte de données et l'analyse de l'année de base sont effectuées à l'aide de modules de collecte de données avec des échantillons de grande taille. L'étape consiste à obtenir des informations sur le marché ou des données connexes via diverses sources et stratégies. Elle comprend l'examen et la planification à l'avance de toutes les données acquises dans le passé. Elle englobe également l'examen des incohérences d'informations observées dans différentes sources d'informations. Les données de marché sont analysées et estimées à l'aide de modèles statistiques et cohérents de marché. De plus, l'analyse des parts de marché et l'analyse des tendances clés sont les principaux facteurs de succès du rapport de marché. Pour en savoir plus, veuillez demander un appel d'analyste ou déposer votre demande.

La méthodologie de recherche clé utilisée par l'équipe de recherche DBMR est la triangulation des données qui implique l'exploration de données, l'analyse de l'impact des variables de données sur le marché et la validation primaire (expert du secteur). Les modèles de données incluent la grille de positionnement des fournisseurs, l'analyse de la chronologie du marché, l'aperçu et le guide du marché, la grille de positionnement des entreprises, l'analyse des brevets, l'analyse des prix, l'analyse des parts de marché des entreprises, les normes de mesure, l'analyse globale par rapport à l'analyse régionale et des parts des fournisseurs. Pour en savoir plus sur la méthodologie de recherche, envoyez une demande pour parler à nos experts du secteur.

Personnalisation disponible

Data Bridge Market Research est un leader de la recherche formative avancée. Nous sommes fiers de fournir à nos clients existants et nouveaux des données et des analyses qui correspondent à leurs objectifs. Le rapport peut être personnalisé pour inclure une analyse des tendances des prix des marques cibles, une compréhension du marché pour d'autres pays (demandez la liste des pays), des données sur les résultats des essais cliniques, une revue de la littérature, une analyse du marché des produits remis à neuf et de la base de produits. L'analyse du marché des concurrents cibles peut être analysée à partir d'une analyse basée sur la technologie jusqu'à des stratégies de portefeuille de marché. Nous pouvons ajouter autant de concurrents que vous le souhaitez, dans le format et le style de données que vous recherchez. Notre équipe d'analystes peut également vous fournir des données sous forme de fichiers Excel bruts, de tableaux croisés dynamiques (Fact book) ou peut vous aider à créer des présentations à partir des ensembles de données disponibles dans le rapport.